Diagonal Bio (9F1) Stock Overview
Provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
9F1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Diagonal Bio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.004 |
| 52 Week High | SEK 0.004 |
| 52 Week Low | SEK 0.0002 |
| Beta | -1.85 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 110.53% |
| 3 Year Change | -94.44% |
| 5 Year Change | n/a |
| Change since IPO | -99.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9F1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | -3.8% |
| 1Y | 110.5% | -7.1% | -5.1% |
Return vs Industry: 9F1 exceeded the German Biotechs industry which returned -30.4% over the past year.
Return vs Market: 9F1 exceeded the German Market which returned 11.3% over the past year.
Price Volatility
| 9F1 volatility | |
|---|---|
| 9F1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 14.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 9F1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 9F1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Karin M. Wehlin | diagonalbio.com |
Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports.
Diagonal Bio AB (publ) Fundamentals Summary
| 9F1 fundamental statistics | |
|---|---|
| Market cap | €600.98k |
| Earnings (TTM) | -€868.10k |
| Revenue (TTM) | €128.06k |
Is 9F1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9F1 income statement (TTM) | |
|---|---|
| Revenue | SEK 1.39m |
| Cost of Revenue | SEK 435.00k |
| Gross Profit | SEK 958.00k |
| Other Expenses | SEK 10.40m |
| Earnings | -SEK 9.44m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0058 |
| Gross Margin | 68.77% |
| Net Profit Margin | -677.89% |
| Debt/Equity Ratio | 0% |
How did 9F1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 13:37 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Diagonal Bio AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.